VTRS: Viatris Inc. Stocks News on October 26, 2025

Viatris to Participate in Upcoming Investor Conferences

VTRS

PR Newswire

13 days ago

Viatris to Participate in Upcoming Investor Conferences

World Mental Health Day 2025: Empowering Minds, Breaking Barriers

VTRS

ACCESS Newswire

16 days ago

World Mental Health Day 2025: Empowering Minds, Breaking Barriers

Does Viatris Offer Opportunity After Recent European Approval Boost?

VTRS

Simply Wall St.

17 days ago

Does Viatris Offer Opportunity After Recent European Approval Boost?

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

VTRS

PR Newswire

25 days ago

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

3 Cash-Producing Stocks We Keep Off Our Radar

VTRS

StockStory

25 days ago

3 Cash-Producing Stocks We Keep Off Our Radar

VTRS

Insider Monkey

a month ago

Viatris Inc. (VTRS) Enters $515M IV Iron Market With FDA Green Light

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

VTRS

GlobeNewswire

2 months ago

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

VTRS

StockStory

2 months ago

Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

VTRS

PR Newswire

2 months ago

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

The 5 Most Interesting Analyst Questions From Viatris’s Q1 Earnings Call

VTRS

StockStory

4 months ago

The 5 Most Interesting Analyst Questions From Viatris’s Q1 Earnings Call

Viatris gains China approval for Yupelri to treat COPD

VTRS

Pharmaceutical Technology

4 months ago

Viatris gains China approval for Yupelri to treat COPD

Viatris’ presbyopia drug clears second Phase III trial

VTRS

Clinical Trials Arena

4 months ago

Viatris’ presbyopia drug clears second Phase III trial

VTRS

MT Newswires

4 months ago

Sector Update: Health Care Stocks Steady Pre-Bell Thursday

VTRS

MT Newswires

4 months ago

Sector Update: Health Care

VTRS

MT Newswires

4 months ago

Viatris Says Late-Stage Study of MR-141 in Presbyopia Meets Primary, Secondary Endpoints

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

VTRS

PR Newswire

4 months ago

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

VTRS

MT Newswires

4 months ago

Theravance Biopharma Earns $7.5 Million Milestone Payment After COPD Drug Wins China Approval

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

VTRS

PR Newswire

4 months ago

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

Is Viatris Stock Underperforming the S&P 500?

VTRS

Barchart

4 months ago

Is Viatris Stock Underperforming the S&P 500?

3 Unprofitable Stocks with Mounting Challenges

VTRS

StockStory

4 months ago

3 Unprofitable Stocks with Mounting Challenges

VTRS

StockStory

4 months ago

3 Reasons to Avoid VTRS and 1 Stock to Buy Instead

3 Healthcare Stocks with Questionable Fundamentals

VTRS

StockStory

4 months ago

3 Healthcare Stocks with Questionable Fundamentals

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

VTRS

PR Newswire

4 months ago

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

VTRS

Zacks

5 months ago

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

VTRS

Zacks

5 months ago

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

VTRS

StockStory

5 months ago

VTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost Review

VTRS

Insider Monkey

5 months ago

Viatris (VTRS) Faces Securities Fraud Class Action Over FDA Inspection Fallout

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises

VTRS

Zacks

5 months ago

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises

$Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions$

VTRS

PR Newswire

5 months ago

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada

VTRS

CNW Group

5 months ago

Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada

VTRS

StockStory

5 months ago

3 Stocks Under $10 Skating on Thin Ice

Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers

VTRS

StockStory

5 months ago

Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers

VTRS

PR Newswire

5 months ago

Viatris to Participate in Upcoming Investor Conferences

VTRS

MT Newswires

5 months ago

Piper Sandler Adjusts Price Target on Viatris to $9 From $10, Maintains Neutral Rating

VTRS

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 05/15/2025

Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

VTRS

StockStory

5 months ago

Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y

VTRS

Zacks

6 months ago

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y

VTRS

GuruFocus.com

6 months ago

Viatris Inc (VTRS) Q1 2025 Earnings Call Highlights: Navigating Challenges and Capitalizing on ...

VTRS

Thomson Reuters StreetEvents

6 months ago

Q1 2025 Viatris Inc Earnings Call

VTRS

Morningstar Research

6 months ago

Analyst Report: Viatris Inc.

Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains

VTRS

Zacks

6 months ago

Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains

VTRS

StockStory

6 months ago

Viatris (NASDAQ:VTRS) Reports Sales Below Analyst Estimates In Q1 Earnings, But Stock Soars 8%

VTRS

Zacks

6 months ago

Viatris (VTRS) Reports Q1 Earnings: What Key Metrics Have to Say

VTRS

Zacks

6 months ago

Viatris (VTRS) Beats Q1 Earnings and Revenue Estimates

Viatris’ new form of old pain drug scores in large trials

VTRS

BioPharma Dive

6 months ago

Viatris’ new form of old pain drug scores in large trials

VTRS

MT Newswires

6 months ago

Viatris' Q1 Adjusted Earnings, Revenue Decline; 2025 Adjusted EPS Outlook Raised

VTRS

Associated Press Finance

6 months ago

Viatris: Q1 Earnings Snapshot

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook

VTRS

PR Newswire

6 months ago

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook

Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential

VTRS

PR Newswire

6 months ago

Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential

Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain

VTRS

PR Newswire

6 months ago

Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain

VTRS

PR Newswire

6 months ago

Viatris Announces Quarterly Dividend

VTRS

StockStory

6 months ago

Viatris Earnings: What To Look For From VTRS

VTRS

MT Newswires

6 months ago

Sector Update: Health Care Stocks Fall Late Afternoon

VTRS

MT Newswires

6 months ago

Heron Settles Patent Litigation With Mylan Over Cinvanti, Aponvie; Shares Rise

Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors

VTRS

PR Newswire

6 months ago

Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors

VTRS

Zacks

6 months ago

Unveiling Viatris (VTRS) Q1 Outlook: Wall Street Estimates for Key Metrics

2 S&P 500 Stocks Worth Investigating and 1 to Avoid

VTRS

StockStory

6 months ago

2 S&P 500 Stocks Worth Investigating and 1 to Avoid

Viatris Q1 Earnings Release: What's in Store for the Stock?

VTRS

Zacks

6 months ago

Viatris Q1 Earnings Release: What's in Store for the Stock?

VTRS

Zacks

6 months ago

Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for

VTRS

Insider Monkey

6 months ago

Viatris Inc. (VTRS): Among the Worst Performing Stocks in S&P 500 So Far in 2025

VTRS

Insider Monkey

6 months ago

Viatris Inc. (VTRS): One of the Cheap Quarterly Dividend Stocks to Buy Now

VTRS

StockStory

6 months ago

Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest

VTRS

Insider Monkey

6 months ago

Viatris Inc. (VTRS): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential

Viatris to Present at the BofA Securities 2025 Healthcare Conference

VTRS

PR Newswire

6 months ago

Viatris to Present at the BofA Securities 2025 Healthcare Conference

VTRS

StockStory

6 months ago

3 Reasons VTRS is Risky and 1 Stock to Buy Instead

VTRS

Insider Monkey

6 months ago

Is Viatris Inc. (NASDAQ:VTRS) the Best Cheap Stock to Buy Under $10?

VTRS

MT Newswires

6 months ago

BofA Trims Price Target on Viatris to $8 From $10

VTRS

MT Newswires

6 months ago

Sector Update: Health Care Stocks Fall Pre-Bell Monday

VTRS

MT Newswires

6 months ago

Viatris Applies for Japan Approval of Effexor to Treat Generalized Anxiety Disorder

Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder

VTRS

PR Newswire

6 months ago

Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder

Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

VTRS

StockStory

6 months ago

Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

VTRS

Insider Monkey

6 months ago

Is Viatris Inc. (VTRS) The Top Healthcare Stock to Buy According to Billionaire David Einhorn?

Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer

VTRS

PR Newswire

6 months ago

Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer

VTRS

Insider Monkey

6 months ago

Viatris Inc. (VTRS): Among the High-Dividend Stocks to Invest In Under $10

VTRS

StockStory

7 months ago

3 Hated Stocks with Mounting Challenges

3 Beaten-Down Stocks That Are Trading Below Their Book Values

VTRS

Motley Fool

7 months ago

3 Beaten-Down Stocks That Are Trading Below Their Book Values

Viatris to Pay $335 Million for Settlement of Opioid-Related Claims

VTRS

Zacks

7 months ago

Viatris to Pay $335 Million for Settlement of Opioid-Related Claims

Viatris to Pay Up to $335 Million in Opioid Settlement

VTRS

GuruFocus.com

7 months ago

Viatris to Pay Up to $335 Million in Opioid Settlement

VTRS

MT Newswires

7 months ago

Viatris to Settle Opioid Claims Through Nationwide Framework

Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims

VTRS

PR Newswire

7 months ago

Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims

VTRS

Morningstar Research

7 months ago

Analyst Report: Viatris Inc.

VTRS

Insider Monkey

7 months ago

Viatris Inc. (VTRS): Among the Oversold Stocks to Buy in 2025 Amid Inflation Fears

Viatris to Report First Quarter 2025 Financial Results on May 8, 2025

VTRS

PR Newswire

7 months ago

Viatris to Report First Quarter 2025 Financial Results on May 8, 2025

VTRS

Insider Monkey

7 months ago

Is Viatris Inc. (NASDAQ:VTRS) One of The Best Stocks to Buy According to Billionaire David Einhorn?

Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment

VTRS

StockStory

7 months ago

Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment

VTRS

Insider Monkey

7 months ago

Is Viatris Inc. (VTRS) the Best Nasdaq Stock Under $20 to Buy Now?

VTRS

Argus Research

7 months ago

Analyst Report: Viatris Inc

VTRS

Argus Research

7 months ago

Market Update: DKS, SLF, LYB, VTRS

Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks

VTRS

StockStory

7 months ago

Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks

1 Healthcare Stock to Target This Week and 2 to Turn Down

VTRS

StockStory

8 months ago

1 Healthcare Stock to Target This Week and 2 to Turn Down

VTRS

Insider Monkey

8 months ago

Why Viatris Inc. (VTRS) Is Plunging So Far In 2025

VTRS

MT Newswires

8 months ago

Jefferies Adjusts Viatris Price Target to $13 From $15, Maintains Buy Rating

Viatris to Present at the Barclays 27th Annual Global Healthcare Conference

VTRS

PR Newswire

8 months ago

Viatris to Present at the Barclays 27th Annual Global Healthcare Conference

VTRS

MT Newswires

8 months ago

Piper Sandler Adjusts Price Target on Viatris to $10 From $14, Maintains Neutral Rating

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

VTRS

StockStory

8 months ago

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

VTRS

Insider Monkey

8 months ago

Is Viatris Inc. (VTRS) the Best Weight Loss Drug Stock to Buy According to Analysts?

VTRS

Zacks

8 months ago

Here's What Key Metrics Tell Us About Viatris (VTRS) Q4 Earnings

VTRS

MT Newswires

8 months ago

Barclays Adjusts Price Target on Viatris to $9 From $12, Keeps Underweight Rating

VTRS

Insider Monkey

8 months ago

Why Viatris Inc. (VTRS) Went Down on Thursday

VTRS

Thomson Reuters StreetEvents

8 months ago

Latest Viatris Inc. (VTRS) News on October 26, 2025

Share on Social Networks: